Shots:

• Sanofi to acquire Synthrox in all-cash transactions at $68/share- making a total deal value $2.5B with a premium of 172% to Synthorx’s closing price on December 6- 2019. The transaction is expected to be completed in Q1’20
• The focus of the acquisition is to foster Sanofi’s immuno-oncology (IO) pipeline with the addition of Synthorx’s THOR-707. Additionally- Synthorx’s Expanded Genetic Alphabet platform is expected to display synergistic effect with Sanofi’s platforms including Nanobody technology- enabling it to develop novel therapies for oncology and other therapeutic areas
• Synthorx’s THOR-707 is a variant of IL-2- being evaluated for multiple solid tumors as monothx or in combination with immune checkpoint inhibitors. Sanofi expects THOR-707 to shown therapeutic activity when combined with its pre/-clinical oncology assets including PD-1- CD-38- and molecules modulating effector T-cells and NK cells and pursue it as a foundation of future IO-IO combinations

Click here to­ read full press release/ article | Ref: Businesswire | Image: PRNewswire